groundreaking youth discovery..what if?
StockMarketNewsAlert.com NEW Corporate Stock Alert ~~~~~~~~~~~~~~~~~~~~~~~~~~
What if You just found a company that has a groundbreaking product that can solve many problems for many healthcare companies that specialize in medical cell therapies, organ transplant, trauma, blood product banking and anti-inflammation.
What if That same company is being investigated by companies for targeting commercial entities specializing in regenerative medicine, cellular and tissue therapies, organ transplantation, trauma, blood product banking, anti- inflammation and cosmetics/skin care and is involved in discussions with a number of small and large, Fortune 500 companies to bring life-enhancing products to market.
What if That company is presently unknown on Wall-Street RIGHT NOW and trades for mere pennies per share….actually 13 cents per share.
We`ve found that company ProtoKinetix (OTCBB:PKTX) is a biotech company focused on developing and licensing patented anti-aging glycopeptides (AAGP(TM)) to the health care, biotechnology and skin care/ cosmetic industries.
Since 2005, ProtoKinetix has been engaged in groundbreaking scientific research.
Several recent tests and trials on ProtoKinetix` AAGP(TM) cryopreservation (freezing cells to -196°C) has shown promising results acrossmultiple cell lines. AAGP(TM) molecules have demonstrated to enhance the health and extend the life of cells and seem to carry anti-inflammatory properties.
ProtoKinetix is the first company to make a stable and non-toxic version.
ProtoKinetix is in discussions with a number small and large, Fortune 500 companies to bring life-enhancing AAGP(TM) containing products to market. In September 2008, ProtoKinetix announced its first commercial contract to manufacture AAGP(TM) as the primary active ingredient in an anti-inflammatory sports cream in the US. This contract is one of several in the pipeline that is positioning ProtoKinetix on a path of rapid revenue growth and commercial success.
ProtoKinetix (PKTX) has many applications …. too many to mention in one email.
To get a full understanding about this groundbreaking company go to http://www.protokinetix.com/
++++++++++++++++++ Our NEW company is (OTC: PKTX) Over the next several days PKTX could breakout past its previous highs.
Short Term Target:$0.45 Long Term Target:$8.00 PKTX – http://moneycentral.msn.com/detail/stock_quotesymbol=pktx Cell therapy is a field of medicine that uses cells to repair tissues and organs that have been damaged by human disease or to generate new tissues with desired functional activities. Medical science is making considerable progress in research and developing therapies using embryonic and adult stem cells.
At the same time the use of blood component cells in transfusions and organ transplants continue to be an important part of many medical treatments. Cells, tissues and organs all need to survive with enhanced health for these procedures to be more effective.
ProtoKinetix` anti-aging glycopeptides, trademarked as AAGPs(TM), have demonstrated in tests the ability to enhance the health and extend the life of biologically sensitive cells which have been subjected to acute stress conditions under laboratory controlled protocols. AAGPs(TM) have shown to be stable and non-toxic.
ProtoKinetix owns the world-wide rights to this family of anti-aging glycopeptides.
Since inception in 2004, ProtoKinetix has primarily focused on scientific research, but the company is now in the process of directing major efforts to the practical side of commercialization. The commercial applications for AAGPs(TM) in large markets such as skincare/cosmetic products and targeted health care solutions are numerous.
ProtoKinetix is currently working with leading businesses to bring AAGP(TM) to market With a versatile biotechnology platform in place, ProtoKinetix has entered into discussions with a number small and large, Fortune 500 companies to bring life-enhancing AAGP(TM) containing products to market. In September 2008, ProtoKinetix announced its first commercial contract to manufacture AAGP(TM) as the primary active ingredient in an anti-inflammatory sports cream in the US. This contract is one of several in the pipeline that is positioning ProtoKinetix on a path of rapid revenue growth and commercial success.
The Staff StockMarketNewsAlert email:
info@stockmarketnewsalert.com [mailto:info@stockmarketnewsalert.com] http://www.stockmarketnewsalert.com ph: 561-807-6350 *Never invest into a stock we discuss unless you can afford to lose your entire investment ~~~~~~~~~~~~~~~~~~~~~~~~~~
DISCLAIMER & RISK DISCLOSURE: First Equity Group Inc Inc (StockMarketNewsAlert and SizzleStocks.com) and our affiliates (“our companies”) are not registered investment advisers or broker/dealers. Our companies make no commitment that the purchase of securities of companies profiled or otherwise mentioned in our websites are suitable or advisable for any person or that an investment such securities will be profitable.
FEG compensation for advertising is five hundred thousand shares restricted 144 stock for ninety days . In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We profile selected companies on our site. Most of these companies provide compensation for profile coverage. Specific questions on membership or profiles can be obtained by writing the Publisher at: info@Stockmarketnewsalert.com [mailto:info@Stockmarketnewsalert.com].
~~~~~~~~~~~~~~~~~~~~~~~~~~
No related posts.